Li Chunpu, Yu Xin, Guo Dongmei, Liu Guanhua, Zhang Kaigang, Teng Qingliang, Lin Hai
Department of Orthopedics, Taian City Central Hospital, Taian, China.
Department of Orthopedics, Qilu Hospital, Shandong University, Jinan, China.
Onco Targets Ther. 2018 Jun 18;11:3495-3504. doi: 10.2147/OTT.S158167. eCollection 2018.
Some previous studies have sought to investigate the roles of excision repair cross complementation group 1 (), , , and gene polymorphisms in the prognosis of osteosarcoma patients. However, their results were inconclusive. Here, we performed a meta-analysis to determine the strength of the association between eight polymorphisms in the genes (rs11615, rs3212986, rs2298881, rs13181, rs1799793, rs1800067, rs2296147, and rs1047768) and prognosis of osteosarcoma patients treated with chemotherapy.
We retrieved the relevant studies from PubMed, Embase, and Web of Science in human osteosarcoma published prior to July 2017. Primary outcomes included overall survival (OS) and event-free survival, expressed by hazard ratios (HRs) with their corresponding 95% CIs. STATA software (version 12.0) was utilized to perform data synthesis.
A total of 13 eligible follow-up studies involving 2,303 patients met all the inclusion criteria, conducted in two populations of ethnic descent: 11 Asians and two Caucasians. In the present meta-analysis, we demonstrated that the homozygous variant genotypes in rs1799793 and rs2296147 were significantly associated with OS in osteosarcoma (TT vs GG for rs1799793: HR = 0.62, 95% CI = 0.41-0.93, = 0.310, = 15.3%, = 0.020; TT vs CC for rs2296147: HR = 0.42, 95% CI = 0.23-0.78, = 0.708, = 0.0%, = 0.006). In addition, no evidence of association was observed between prognosis in osteosarcoma and rs11615, rs3212986, rs2298881, rs13181, rs1800067, and rs1047768 polymorphisms.
Our meta-analysis indicated that TT genotype in the rs1799793 and rs2296147 might prolong the survival time of patients with osteosarcoma, suggesting that the rs1799793 and rs2296147 polymorphisms can be used as predictors for prognosis of osteosarcoma patients treated with chemotherapy.
此前一些研究试图探究切除修复交叉互补基因1（ERCC1）、XPF、XPG和ERCC4基因多态性在骨肉瘤患者预后中的作用。然而，他们的结果尚无定论。在此，我们进行了一项荟萃分析，以确定ERCC基因中的8个多态性位点（rs11615、rs3212986、rs2298881、rs13181、rs1799793、rs1800067、rs2296147和rs1047768）与接受化疗的骨肉瘤患者预后之间关联的强度。
我们从PubMed、Embase和Web of Science中检索了2017年7月之前发表的关于人类骨肉瘤的相关研究。主要结局包括总生存期（OS）和无事件生存期，以风险比（HRs）及其相应的95%置信区间表示。使用STATA软件（版本12.0）进行数据合成。
共有13项符合条件的随访研究，涉及2303例患者，均符合所有纳入标准，研究对象为两个种族群体：11例亚洲人和2例高加索人。在本荟萃分析中，我们证明ERCC1基因rs1799793和ERCC4基因rs2296147的纯合变异基因型与骨肉瘤的OS显著相关（rs1799793的TT与GG相比：HR = 0.62，95% CI = 0.41 - 0.93，I² = 0.310，P = 15.3%，P = 0.020；rs2296147的TT与CC相比：HR = 0.42，95% CI = 0.23 - 0.78，I² = 0.708，P = 0.0%，P = 0.006）。此外，未观察到骨肉瘤预后与ERCC1基因rs11615、rs3212986、rs2298881、rs13181、rs1800067以及ERCC4基因rs1047768多态性之间存在关联的证据。
我们的荟萃分析表明，ERCC1基因rs1799793和ERCC4基因rs2296147的TT基因型可能延长骨肉瘤患者的生存时间，这表明rs1799793和rs2296147多态性可作为接受化疗的骨肉瘤患者预后的预测指标。
